{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:39:16Z","timestamp":1773797956842,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008591","name":"Fondazione Grigioni per il Morbo di Parkinson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008591","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00415-025-13598-9","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:23:07Z","timestamp":1768555387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is Parkinson\u2019s disease getting older? Demographic and modifiable determinants of age at onset in a large Italian tertiary care cohort"],"prefix":"10.1007","volume":"273","author":[{"given":"Elena","family":"Contaldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Calandrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Sacilotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Zini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Del Sorbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Soliveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Zecchinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis U.","family":"Isaias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Pezzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"13598_CR1","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","volume":"15","author":"A Ascherio","year":"2016","unstructured":"Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson\u2019s disease: risk factors and prevention. Lancet Neurol 15:1257\u20131272. https:\/\/doi.org\/10.1016\/S1474-4422(16)30230-7","journal-title":"Lancet Neurol"},{"key":"13598_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 8:S3\u2013S8. https:\/\/doi.org\/10.3233\/JPD-181474","journal-title":"J Parkinsons Dis"},{"key":"13598_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaneurol.2016.0947","volume":"73","author":"R Savica","year":"2016","unstructured":"Savica R, Grossardt BR, Bower JH et al (2016) Time trends in the incidence of Parkinson disease. JAMA Neurol 73:981. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0947","journal-title":"JAMA Neurol"},{"key":"13598_CR4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/aje\/kwv271","volume":"183","author":"SKL Darweesh","year":"2016","unstructured":"Darweesh SKL, Koudstaal PJ, Stricker BH et al (2016) Trends in the incidence of Parkinson disease in the general population: the Rotterdam study. Am J Epidemiol 183:1018\u20131026. https:\/\/doi.org\/10.1093\/aje\/kwv271","journal-title":"Am J Epidemiol"},{"key":"13598_CR5","doi-asserted-by":"publisher","first-page":"14670","DOI":"10.1038\/s41598-024-65640-x","volume":"14","author":"C Gabbert","year":"2024","unstructured":"Gabbert C, Bl\u00f6baum L, L\u00fcth T et al (2024) The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson\u2019s disease. Sci Rep 14:14670. https:\/\/doi.org\/10.1038\/s41598-024-65640-x","journal-title":"Sci Rep"},{"key":"13598_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neuro.2024.12.003","volume":"106","author":"SW Hong","year":"2025","unstructured":"Hong SW, Page R, Truman P (2025) Smoking, coffee intake, and Parkinson\u2019s disease: potential protective mechanisms and components. Neurotoxicology 106:48\u201363. https:\/\/doi.org\/10.1016\/j.neuro.2024.12.003","journal-title":"Neurotoxicology"},{"key":"13598_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.963163","volume":"13","author":"J Shi","year":"2022","unstructured":"Shi J, Tian J, Fan Y et al (2022) Intelligence, education level, and risk of Parkinson\u2019s disease in European populations: a Mendelian randomization study. Front Genet 13:963163. https:\/\/doi.org\/10.3389\/fgene.2022.963163","journal-title":"Front Genet"},{"key":"13598_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12940-020-00624-8","volume":"19","author":"MP Schneider Medeiros","year":"2020","unstructured":"Schneider Medeiros MP, Reddy SP, Socal M et al (2020) Occupational pesticide exposure and the risk of death in patients with Parkinson\u2019s disease: an observational study in southern Brazil. Environ Health 19:68. https:\/\/doi.org\/10.1186\/s12940-020-00624-8","journal-title":"Environ Health"},{"key":"13598_CR9","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3233\/JPD-212725","volume":"11","author":"K Komici","year":"2021","unstructured":"Komici K, Femminella GD, Bencivenga L et al (2021) Diabetes mellitus and Parkinson\u2019s disease: a systematic review and meta-analyses. JPD 11:1585\u20131596. https:\/\/doi.org\/10.3233\/JPD-212725","journal-title":"JPD"},{"key":"13598_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00306","volume":"11","author":"F Siani","year":"2017","unstructured":"Siani F, Greco R, Levandis G et al (2017) Influence of estrogen modulation on glia activation in a murine model of Parkinson\u2019s disease. Front Neurosci 11:306. https:\/\/doi.org\/10.3389\/fnins.2017.00306","journal-title":"Front Neurosci"},{"key":"13598_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181\u2013184. https:\/\/doi.org\/10.1136\/jnnp.55.3.181","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13598_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/brainsci12050536","volume":"12","author":"JM Morowitz","year":"2022","unstructured":"Morowitz JM, Pogson KB, Roque DA, Church FC (2022) Role of SARS-CoV-2 in modifying neurodegenerative processes in Parkinson\u2019s disease: a narrative review. Brain Sci 12:536. https:\/\/doi.org\/10.3390\/brainsci12050536","journal-title":"Brain Sci"},{"key":"13598_CR13","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.ncl.2016.06.012","volume":"34","author":"A Lee","year":"2016","unstructured":"Lee A, Gilbert RM (2016) Epidemiology of Parkinson disease. Neurol Clin 34:955\u2013965. https:\/\/doi.org\/10.1016\/j.ncl.2016.06.012","journal-title":"Neurol Clin"},{"key":"13598_CR14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3233\/JPD-230104","volume":"14","author":"A K\u00f6nig","year":"2024","unstructured":"K\u00f6nig A, Outeiro TF (2024) Diabetes and Parkinson\u2019s disease: understanding shared molecular mechanisms. J Parkinsons Dis 14:917\u2013924. https:\/\/doi.org\/10.3233\/JPD-230104","journal-title":"J Parkinsons Dis"},{"key":"13598_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/acn3.51343","volume":"8","author":"R Ou","year":"2021","unstructured":"Ou R, Wei Q, Hou Y et al (2021) Effect of diabetes control status on the progression of Parkinson\u2019s disease: a prospective study. Ann Clin Transl Neurol 8:887\u2013897. https:\/\/doi.org\/10.1002\/acn3.51343","journal-title":"Ann Clin Transl Neurol"},{"key":"13598_CR16","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1007\/s00415-022-11496-y","volume":"270","author":"G Pezzoli","year":"2023","unstructured":"Pezzoli G, Cereda E, Amami P et al (2023) Onset and mortality of Parkinson\u2019s disease in relation to type II diabetes. J Neurol 270:1564\u20131572. https:\/\/doi.org\/10.1007\/s00415-022-11496-y","journal-title":"J Neurol"},{"key":"13598_CR17","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3390\/pharmaceutics14050946","volume":"14","author":"K-H Huang","year":"2022","unstructured":"Huang K-H, Chang Y-L, Gau S-Y et al (2022) Dose-response association of metformin with Parkinson\u2019s disease odds in type 2 diabetes mellitus. Pharmaceutics 14:946. https:\/\/doi.org\/10.3390\/pharmaceutics14050946","journal-title":"Pharmaceutics"},{"key":"13598_CR18","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C et al (2024) Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med 390:1176\u20131185. https:\/\/doi.org\/10.1056\/NEJMoa2312323","journal-title":"N Engl J Med"},{"key":"13598_CR19","doi-asserted-by":"publisher","first-page":"22489","DOI":"10.1038\/s41598-023-49870-z","volume":"13","author":"Y-H Lin","year":"2023","unstructured":"Lin Y-H, Hsu C-C, Liu J-S et al (2023) Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson\u2019s disease in diabetic patients. Sci Rep 13:22489. https:\/\/doi.org\/10.1038\/s41598-023-49870-z","journal-title":"Sci Rep"},{"key":"13598_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209805","volume":"103","author":"HK Kim","year":"2024","unstructured":"Kim HK, Biessels GJ, Yu MH et al (2024) SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes. Neurology 103:e209805. https:\/\/doi.org\/10.1212\/WNL.0000000000209805","journal-title":"Neurology"},{"key":"13598_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00415-025-12989-2","volume":"272","author":"C Malatt","year":"2025","unstructured":"Malatt C, Maghzi H, Hogg E et al (2025) Adrenergic blockers, statins, and non-steroidal anti-inflammatory drugs are associated with later age at onset in Parkinson\u2019s disease. J Neurol 272:255. https:\/\/doi.org\/10.1007\/s00415-025-12989-2","journal-title":"J Neurol"},{"key":"13598_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.837890","volume":"13","author":"Y Jo","year":"2022","unstructured":"Jo Y, Kim S, Ye BS et al (2022) Protective effect of renin-angiotensin system inhibitors on Parkinson\u2019s disease: a nationwide cohort study. Front Pharmacol 13:837890. https:\/\/doi.org\/10.3389\/fphar.2022.837890","journal-title":"Front Pharmacol"},{"key":"13598_CR23","doi-asserted-by":"publisher","first-page":"1107248","DOI":"10.3389\/fphar.2023.1107248","volume":"14","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Gu X-J, Su W-M et al (2023) Protective effect of antihypertensive drugs on the risk of Parkinson\u2019s disease lacks causal evidence from mendelian randomization. Front Pharmacol 14:1107248. https:\/\/doi.org\/10.3389\/fphar.2023.1107248","journal-title":"Front Pharmacol"},{"key":"13598_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae195","volume":"6","author":"S Ge","year":"2024","unstructured":"Ge S, Zha L, Kimura Y et al (2024) Statin use and risk of Parkinson\u2019s disease among older adults in Japan: a nested case\u2013control study using the Longevity Improvement and Fair Evidence study. Brain Commun 6:fcae195. https:\/\/doi.org\/10.1093\/braincomms\/fcae195","journal-title":"Brain Commun"},{"key":"13598_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/mds.27006","volume":"32","author":"G Liu","year":"2017","unstructured":"Liu G, Sterling NW, Kong L et al (2017) Statins may facilitate Parkinson\u2019s disease: Insight gained from a large, national claims database: Statins and PD Risk: An Observational Study. Mov Disord 32:913\u2013917. https:\/\/doi.org\/10.1002\/mds.27006","journal-title":"Mov Disord"},{"key":"13598_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/6465793","volume":"2016","author":"L Polito","year":"2016","unstructured":"Polito L, Greco A, Seripa D (2016) Genetic profile, environmental exposure, and their interaction in Parkinson\u2019s disease. Parkinson\u2019s Disease 2016:1\u20139. https:\/\/doi.org\/10.1155\/2016\/6465793","journal-title":"Parkinson\u2019s Disease"},{"key":"13598_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1515\/reveh-2021-0111","volume":"38","author":"T Chambers-Richards","year":"2023","unstructured":"Chambers-Richards T, Su Y, Chireh B, D\u2019Arcy C (2023) Exposure to toxic occupations and their association with Parkinson\u2019s disease: a systematic review with meta-analysis. Rev Environ Health 38:65\u201383. https:\/\/doi.org\/10.1515\/reveh-2021-0111","journal-title":"Rev Environ Health"},{"key":"13598_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2024.172838","volume":"931","author":"A Aravindan","year":"2024","unstructured":"Aravindan A, Newell ME, Halden RU (2024) Literature review and meta-analysis of environmental toxins associated with increased risk of Parkinson\u2019s disease. Sci Total Environ 931:172838. https:\/\/doi.org\/10.1016\/j.scitotenv.2024.172838","journal-title":"Sci Total Environ"},{"key":"13598_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.parkreldis.2017.09.022","volume":"45","author":"AF Gigante","year":"2017","unstructured":"Gigante AF, Martino T, Iliceto G, Defazio G (2017) Smoking and age-at-onset of both motor and non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord 45:94\u201396. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.022","journal-title":"Parkinsonism Relat Disord"},{"key":"13598_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/oxfordjournals.aje.a113182","volume":"114","author":"DG Haack","year":"1981","unstructured":"Haack DG, Baumann RJ, McKEAN HE et al (1981) Nicotine exposure and Parkinson disease. Am J Epidemiol 114:191\u2013200. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a113182","journal-title":"Am J Epidemiol"},{"key":"13598_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117534","volume":"427","author":"S Neshige","year":"2021","unstructured":"Neshige S, Ohshita T, Neshige R, Maruyama H (2021) Influence of current and previous smoking on current phenotype in Parkinson\u2019s disease. J Neurol Sci 427:117534. https:\/\/doi.org\/10.1016\/j.jns.2021.117534","journal-title":"J Neurol Sci"},{"key":"13598_CR32","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1212\/01.wnl.0000184520.21744.a2","volume":"65","author":"R Frigerio","year":"2005","unstructured":"Frigerio R, Elbaz A, Sanft KR et al (2005) Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology 65:1575\u20131583. https:\/\/doi.org\/10.1212\/01.wnl.0000184520.21744.a2","journal-title":"Neurology"},{"key":"13598_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01135-3","volume":"7","author":"F Lin","year":"2024","unstructured":"Lin F, Lin Y, Chen L et al (2024) Association of physical activity pattern and risk of Parkinson\u2019s disease. NPJ Digit Med 7:137. https:\/\/doi.org\/10.1038\/s41746-024-01135-3","journal-title":"NPJ Digit Med"},{"key":"13598_CR34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00415-011-6302-8","volume":"259","author":"M Poletti","year":"2012","unstructured":"Poletti M, Bonuccelli U (2012) Personality traits in patients with Parkinson\u2019s disease: assessment and clinical implications. J Neurol 259:1029\u20131038. https:\/\/doi.org\/10.1007\/s00415-011-6302-8","journal-title":"J Neurol"},{"key":"13598_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/02601370.2024.2343013","volume":"43","author":"DE S\u00f6rman","year":"2024","unstructured":"S\u00f6rman DE, \u00c5str\u00f6m E, Ahlstr\u00f6m M et al (2024) The influence of personality traits on engagement in lifelong learning. Int J Lifelong Educ 43:259\u2013276. https:\/\/doi.org\/10.1080\/02601370.2024.2343013","journal-title":"Int J Lifelong Educ"},{"key":"13598_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105479","volume":"156","author":"M Bourque","year":"2024","unstructured":"Bourque M, Morissette M, Di Paolo T (2024) Neuroactive steroids and Parkinson\u2019s disease: review of human and animal studies. Neurosci Biobehav Rev 156:105479. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105479","journal-title":"Neurosci Biobehav Rev"},{"key":"13598_CR37","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/jnnp-2020-323646","volume":"91","author":"BM Jacobs","year":"2020","unstructured":"Jacobs BM, Belete D, Bestwick J et al (2020) Parkinson\u2019s disease determinants, prediction and gene\u2013environment interactions in the UK Biobank. J Neurol Neurosurg Psychiatry 91:1046\u20131054. https:\/\/doi.org\/10.1136\/jnnp-2020-323646","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13598_CR38","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/mds.28760","volume":"36","author":"CDJ Kusters","year":"2021","unstructured":"Kusters CDJ, Paul KC, Duarte Folle A et al (2021) Increased menopausal age reduces the risk of Parkinson\u2019s disease: a Mendelian randomization approach. Mov Disord 36:2264\u20132272. https:\/\/doi.org\/10.1002\/mds.28760","journal-title":"Mov Disord"},{"key":"13598_CR39","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/dev.22085","volume":"63","author":"EJ Hamlat","year":"2021","unstructured":"Hamlat EJ, Prather AA, Horvath S et al (2021) Early life adversity, pubertal timing, and epigenetic age acceleration in adulthood. Dev Psychobiol 63:890\u2013902. https:\/\/doi.org\/10.1002\/dev.22085","journal-title":"Dev Psychobiol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13598-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13598-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13598-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:04:41Z","timestamp":1773785081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13598-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["13598"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13598-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IUI received lecture honoraria and research funding from Medtronic Inc. and Boston Scientific. IUI is a Newronika S.p.A. consultant and shareholder and received funding for research activities from Newronika S.p.A. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Study procedures were approved by the local Ethics Committee (Comitato Etico Territoriale Lombardia 3, protocol 3499\/23), and this research was conducted in accordance with the principles of the Declaration of Helsinki and its subsequent amendments. All participants gave their written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"81"}}